[{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Farmitalia ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Signs LSA for Commercialization of Myring\u2122 in Italy, the Third Biggest Worldwide Market","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Acquires Commercial Rights for Oral Contraceptive Zoely \n","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Merck & Co"},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"TherapeuticsMD ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD and Afaxys Enter Into Agreement","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved ","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Afaxys Pharma"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Gynial","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring\u2122 in Switzerland","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Plushcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Duchesnay"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals Welcomes Swissmedic Approval of Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Evofem Biosciences' Phexxi\u2122 (Lactic acid, Citric acid and Potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Intas Pharmaceuticals","sponsor":"Naari","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Naari Completes Acquisition of ANDAs from Intas Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Intas Pharmaceuticals"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra to Commercialize Myring In France, Poland And UK","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Nurx","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD and Nurx Expand Access to ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nurx"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"$12.0 million","newsHeadline":"AMAG Pharmaceuticals Completes Divestment of Women\u2019s Health Assets","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Palatin Technologies"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$9.0 billion","upfrontCash":"Undisclosed","newsHeadline":"Merck to Focus on Key Growth Pillars Through Spinoff of Women\u2019s Health, Trusted Legacy Brands and Biosimilars Products into New Company","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Merck & Co"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Pivotal Phase 3 AMPOWER Study Results For Phexxi\u2122 in Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Knight Therapeutics"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces U.S. Commercial Launch of Phexxi\u2122, the First and Only Non-Hormonal, Prescription Contraceptive Vaginal Gel","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Knight Therapeutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Supplemental New Drug Application to FDA for Intrauterine Device Mirena\u00ae 52 mg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals to Share New Reproductive Medicine Data at ASRM 2020 Scientific Congress & Expo","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Xiromed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xiromed LLC Launches Gemmily\u2122, First-to-Market Generic to Taytulla\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Xiromed"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"TherapeuticsMD"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Aspen Pharmacare Holdings"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Population Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Population Council and Duchesnay Announce New International License Agreement for ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Duchesnay"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Amring Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amring Pharmaceuticals Inc. Acquires LYSTEDA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","amount":"$263.5 million","upfrontCash":"Undisclosed","newsHeadline":"Richter Announces the Acquisition of Janssen\u2019s Evra\u00ae Transdermal Contraceptive Patch Assets","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMAG Files Submission in Response To the FDA\u2019s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AMAG Pharmaceuticals"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Low-Dose Aspirin May Improve Pregnancy Chances for Women with One or Two Prior Miscarriages-NIH Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"National Institutes of Health"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"TherapeuticsMD"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives Approval for Generic Version of Ortho Evra\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show NEXTSTELLIS\u00ae Has Selective Impact On Endocrine Markers Compared With Common Combined Oral Contraceptives","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mayne Pharma"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie in Talks to Sell $5 Billion Women's Drugs Portfolio","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AbbVie Inc"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EPPPIC Study Reaffirms 17-OHPC for Reducing Early Preterm Birth in High-Risk, Singleton Pregnancies","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"LUXEMBOURG","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Covis Pharma"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Efficacy Data Reinforces NEXTSTELLIS\u00ae Benefits Across Patient Populations","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mayne Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Hosts Organon Investor Day Outlining New Company\u2019s Vision, Focus and Business Model for Sustained Growth","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Merck & Co"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Closing of $50 Million Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Myovant Sciences"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nextstellis\u00ae Receives FDA Marketing Exclusivity and Phase III Data Published","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mayne Pharma"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma and Ferring Pharmaceuticals Enter Into Licensing Agreement for Introducing CARITEC\u00ae in India","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Launches Estradiol Valerate Injection, USP","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Presents New Data at ESHRE 2021 Supporting the Use of Rekovelle (follitropin delta) for Individualized Fertility Treatment","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant - European Commission Approval for RYEQO Treatment ofUterine Fibroid","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Myovant Sciences"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Bayer\u2019s sNDA for Mirena to Prevent Pregnancy for Up to Seven Years","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Introduces Single-Dose Formulation of Carbetocin for Prevention of Postpartum Haemorrhage in India","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Abbott Laboratories"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Amring Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amring Pharmaceuticals Inc. Licenses LYSTEDA to Pierre Fabre for Mexican Market","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pierre Fabre"},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2,100.0 million","newsHeadline":"Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"HRA Pharma"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"INDONESIA","productType":"Large molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Dexa Medica"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety Results from Large Real-World Safety Study in Combined Oral Contraception Published","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Theramex"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Myovant Sciences"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\"House Rules\" Delivers Strong Initial Results and Drives Phexxi Growth","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Iconovo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Granted ICOone\u00ae Patent in China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Peptide","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Iconovo"},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"Agile Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agile Therapeutics and Afaxys Partner to Expand Access to Twirla\u00ae (Levonorgestrel and Ethinyl Estradiol) Transdermal System","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Afaxys Pharma"},{"orgOrder":0,"company":"Theramex","sponsor":"Endoceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Australia Enters Partnership With Endoceutics For Intrarosa\u00ae For The Treatment Of Postmenopausal Vulvovaginal Atrophy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Theramex"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Organon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Organon Acquires Contraceptive Products, Marvelon\u00ae and Mercilon\u00ae, in the People\u2019s Republic of China, Including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Jagdale Industries","sponsor":"Bharat Serums & Vaccines ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Serums and Vaccines Acquires Key Women Health Brand Tidilan from Jagdale Industries","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jagdale Industries"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Merzee\u00ae Capsules in the United States","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Slayback Pharma"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agile Therapeutics\u00ae Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Agile Therapeutics"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE\u00ae for the Management of Moderate to Severe Pain Associated with Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Myovant Sciences"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi\u00ae from Evofem's Phase 3 AMPOWER Clinical Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Agile Therapeutics"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Myovant Sciences"},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theramex Launches Non-hormonal Femarelle\u00ae on the 12th of May","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Theramex"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Effik","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer CenterOne\u2019s Enviero\u00ae Receives First EU Authorization As Part of ESTIMA\u00ae (progesterone) Product Approval","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Pfizer CentreOne"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Proposed Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"TherapeuticsMD"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Myovant Sciences"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covis Pharma Provides Update on FDA Public Hearing for Makena","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"LUXEMBOURG","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Covis Pharma"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phexxi\u00ae Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"ObsEva","sponsor":"Theramex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces European Commission Marketing Authorization for Yselty\u00ae (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ObsEva"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces Results Of 2022 AGM","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Myovant Sciences"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces UK MHRA Marketing Authorization for Yselty\u00ae (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ObsEva"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$26.6 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phexxi\u00ae Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg\/20 mcg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Rubric Capital Management","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"TherapeuticsMD"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE\u00ae, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Myovant Sciences"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Calyptus Pharmaceuticals Announces Partnership with Provepharm to Accelerate Development of an Acute Care Injectable Product","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Calyptus Pharmaceuticals"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akorn Announces FDA-Approved Generic Cetrorelix Acetate for Injection 0.25 mg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Akorn Pharmaceuticals"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calyptus Pharmaceuticals Announces FDA Approval of Cetrorelix Acetate for Injection, 0.25 mg\/vial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Calyptus Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirena\u00ae from Bayer Approved in the US For Extended Duration of Use in Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Launches NativusWell\u00ae, a Novel Nutraceutical for Menopause, in Hong Kong","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Aptorum"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Large Commercial Payer Adds Phexxi\u00ae to Formulary for Standard Plans Nationwide","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Announces Issuance of U.S. Patent Covering Phexxi\u00ae Composition of Matter","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evofem Biosciences"},{"orgOrder":0,"company":"Aurohealth","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Healthcare Brand Launches Nationwide","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Aurohealth"},{"orgOrder":0,"company":"Morningside Pharmaceuticals","sponsor":"Aspire Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"H.I.G. Capital Acquires Morningside Healthcare and Morningside Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Morningside Pharmaceuticals"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene\u00ae, an Investigational Hormone-Free Monthly Intravaginal Contraceptive","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirena\u00ae Approved In Europe For Extended Duration Of Use In Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill\u00ae Daily Oral Contraceptive for Over-The-Counter (OTC) Use","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Perrigo Company plc"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Akorn Pharmaceuticals"},{"orgOrder":0,"company":"Medicines360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Medicines360's LILETTA\u00ae (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Medicines360"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","amount":"$225.7 million","upfrontCash":"$140.0 million","newsHeadline":"TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Mayne Pharma"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","amount":"$225.7 million","upfrontCash":"$140.0 million","newsHeadline":"TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"TherapeuticsMD"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Agile Therapeutics"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Launches NativusWell\u00ae, a Novel Nutraceutical for Menopause, in China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Aptorum"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Emzahh (Norethindrone Tablets USP), 0.35mg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Athenex","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Athenex"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill\u00ae Daily Oral Contraceptive for OTC Use","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Perrigo Company plc"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill\u00ae Daily Oral Contraceptive for OTC Use","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Perrigo Company plc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas' VEOZAH\u2122 (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"Endoceutics","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cosette Pharmaceuticals Acquires Intrarosa\u00ae from Endoceutics, Inc.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Endoceutics"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"vitaCare Prescription Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agile Therapeutics Announces New Agreement with vitaCare\u00ae Prescription Services to Improve Access to Twirla\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Agile Therapeutics"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"Aurisco Pharmaceutical Co.,Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurisco Gets Auxiton (Dydrogesterone) as First Generic Approval in China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Aurisco Pharmaceutical Co.,Ltd"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"This Women's Healthcare Company Raised $7.5 Million in a Public Offering and Says it's Targeting $25 to $30 Million Net Revenue by End of 2023","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Agile Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Organon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Announces Completion of Organon & Co. Spinoff","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Merck & Co"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expanding Access to Women\u2019s Health Fresenius Kabi Launches Generic Fertility Treatment","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Endo International","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo and Premier, Inc. Collaborate to Address Pitocin\u00ae (oxytocin injection, USP) Shortage","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Endo International"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Nonprescription Daily Oral Contraceptive","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Perrigo Company plc"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","amount":"$45.4 million","upfrontCash":"$29.0 million","newsHeadline":"Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma Under Estelle\u00ae Licensing Agreement","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bill & Melinda Gates Foundation, Children\u2019s Investment Fund Foundation, Pfizer and Becton, Dickinson & Company Expand Partnership for Greater Access to Injectable Contraceptive for Women in Low- and Lower-Middle-Income Countries","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Pfizer Inc"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSyent Launches Inofolic\u00ae for Women with Polycystic Ovary Syndrome (PCOS)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"BIOSYENT PHARMA INC"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin's Vyleesi\u00ae Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Palatin Technologies"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marius Pharmaceuticals Expands Access of KYZATREX\u2122 (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military Personnel","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Marius Pharmaceuticals"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Alora® (Estradiol transdermal system) used for Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause, Vulvar and Vaginal Atrophy due to Menopause, Hypoestrogenism Primary Ovarian Failure and Postmenopausal Osteoporosis.
Enviero is first-of-its-kind, a green-chemistry progesterone that represents a step change in progesterone API synthesis, is manufactured via a proprietary biocatalytic process based on plant sterols that reduce waste, greenhouse gas emissions and use of hazardous solvents.
Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy due to menopause.
KYZATREX™ (testosterone undecanoate) is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Estradiol tablets for oral administration, which is indicated for the treatment of moderate to severe vasomotor symptoms associated with the menopause.
Estradiol Gel, 0.1%, is the generic version of the Reference Listed Drug (RLD) Divigel®, an estrogen hormone therapy used to treat moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause.
Inofolic is a natural health product, combining myo-inositol and folic acid in a unique soft-gel capsule for women living with PCOS. Inofolic® helped 70% of women with PCOSii to regulate their menstrual cycles throughout the 16-week study period.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Developments 
Contact Supplier
